Revolutionizing Cancer Therapy
We aspire to create safe and effective therapies for cancer patients through the body’s own immune system.Learn More About Our Therapeutics
Harnessing the Innate Immune System to Combat Checkpoint-Insensitive Tumors
Our lead candidate, AXA-042, is a novel systemically-delivered TLR2/6 agonist that drives anti-tumor response through engagement of the innate immune system.
Targeting a large unmet medical need in oncology
Re-awakening the innate immune system in cancer patients
Overcoming resistance to checkpoint blockade therapy
Generation of long-lasting response in solid tumour indications